AMRX vs RYTM: stock comparison and AI forecast
Amneal Pharmaceuticals, Inc. (AMRX) and Rhythm Pharmaceuticals, Inc. (RYTM) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
AMRX Amneal Pharmaceuticals, Inc.
- Market Cap
- $6.45B
- P/E Ratio
- 61.2x
- Size
- mid-cap
- AI Forecast
RYTM Rhythm Pharmaceuticals, Inc.
- Market Cap
- $6.37B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
- NO CURRENT FORECAST
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- AMRX and RYTM have similar market capitalizations ($6.45B and $6.37B).
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | AMRX | RYTM |
|---|---|---|
| Market Cap | $6.45B | $6.37B |
| P/E Ratio | 61.24x | – |
| P/B Ratio | – | 61.89x |
| EPS | $0.33 | $-3.09 |
| Book Value/Share | – | $1.50 |
| Revenue/Share | $9.76 | $3.48 |
| FCF/Share | $0.40 | – |
Profitability & Margins
| Metric | AMRX | RYTM |
|---|---|---|
| ROE | – | -199.4% |
| ROA | – | -47.0% |
| ROIC | – | -64.0% |
| Gross Margin | 39.3% | 89.0% |
| Operating Margin | – | -83.6% |
| Net Margin | – | -85.6% |
| EBT Margin | – | -85.1% |
| Tax Rate | -7.0% | -0.5% |
Financial Health
| Metric | AMRX | RYTM |
|---|---|---|
| Current Ratio | 2.20x | 3.45x |
| Quick Ratio | 1.44x | 3.20x |
| D/E Ratio | – | 2.14x |
| Financial Leverage | – | 4.25x |
| Interest Coverage | 3.7x | -29.4x |
| Working Capital | $1.06B | $303M |
Cash Flow
| Metric | AMRX | RYTM |
|---|---|---|
| Operating Cash Flow | $201M | -$105M |
| Free Cash Flow | $128M | – |
| Capital Spending | -$73M | – |
| OCF Growth YoY | -42.8% | – |
| FCF Growth YoY | -54.8% | – |
| FCF/Sales | 4.1% | – |
| CapEx/Sales | 2.3% | – |
Operational Efficiency
| Metric | AMRX | RYTM |
|---|---|---|
| Asset Turnover | – | 0.55x |
| Receivables Turnover | – | 5.9x |
| Inventory Turnover | 2.8x | 0.9x |
| Fixed Assets Turnover | 6.8x | 2329.3x |
| Days Sales Outstanding | – | 61 days |
| Days Inventory | 131 days | 422 days |
| Payables Period | – | 224 days |
| Cash Conversion Cycle | – | 260 days |
Income Statement
| Metric | AMRX | RYTM |
|---|---|---|
| Total Revenue | $3.12B | $240M |
| Operating Income | $454M | -$201M |
| Net Income | $0.00M | -$205M |
| R&D Expense | $176M | $173M |
| SG&A Expense | $572M | $241M |
| Cost of Goods Sold | $1.89B | $26M |
Dividend & Shareholder Information
| Metric | AMRX | RYTM |
|---|---|---|
| Shares Outstanding | 319M | 69M |
AMRX vs RYTM: stock comparison and AI forecast
Which is bigger, AMRX or RYTM?
AMRX and RYTM have similar market capitalizations ($6.45B and $6.37B).
Which one does Intratio's AI model rank higher, AMRX or RYTM?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.